Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B Vaccines

• Eduardo Rojas,

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯
• Johanna Hoyos,

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯
• Neil J. Oldfield,

  Affiliation School of Life Sciences, University of Nottingham, Nottingham, United Kingdom

  ⨯
• Philip Lee,

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯
• Mike Flint,

  Current address: Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯
• C. Hal Jones,

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯
• Dlawer A. A. Ala’Aldeen,

  Affiliation School of Life Sciences, University of Nottingham, Nottingham, United Kingdom

  ⨯
• Kathrin U. Jansen,

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯
• Annaliesa S. Anderson

  * E-mail: annaliesa.anderson@pfizer.com

  Affiliation Vaccine Research and Development, Pfizer Inc, Pearl River, New York, United States of America

  ⨯